Nakarai I, Rikitake H, Koga T, Hayashi A, Harada Y, Takamoto M, Ishibashi T, Shinoda A, Sagawa K
Dept. of Surgery, National Sanitorium, Ohmuta Hospital.
Gan To Kagaku Ryoho. 1987 Nov;14(11):3050-7.
Chemotherapy and administration of OK-432 were performed concomitantly in 49 cases of inoperable primary lung cancer, and the Su-PS skin reaction was measured. In the group of patients under 60 years of age, the maximum diameter of the reaction after chemotherapy tended to be large, and evaluation of the results showed that the maximum diameter tended to be large in the group showing tumor contraction effects. In a comparison of the prognosis between the group which survived for less than 6 months and that which survived for 6 months or longer, there was no significant difference between them before administration of OK-432, but when the maximum reaction diameter after chemotherapy was compared, that in the group which survived for 6 months or longer was significantly stronger (p less than 0.05). The Su-PS skin reaction at the time of administration of OK-432 is therefore considered to be a useful immunological parameter for predicting the results of treatment and also for prognosis.
对49例无法手术的原发性肺癌患者同时进行化疗和OK-432给药，并测量Su-PS皮肤反应。在60岁以下的患者组中，化疗后反应的最大直径倾向于较大，结果评估显示，显示肿瘤缩小效果的组中最大直径倾向于较大。在存活时间少于6个月的组和存活6个月或更长时间的组之间的预后比较中，在给予OK-432之前，两组之间没有显著差异，但比较化疗后的最大反应直径时，存活6个月或更长时间的组的反应明显更强（p<0.05）。因此，给予OK-432时的Su-PS皮肤反应被认为是预测治疗结果以及预后的有用免疫参数。
